Compare Abeona Therapeutics Inc (ABEO) vs Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $28.93. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | RDTE | |
|---|---|---|
Market Cap | $424.33M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.45 | $34.20 |
52-Week Low | $4.17 | $26.40 |
Enterprise Value | $279.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
RDTE trades at $28.91, up 1.19% today, but technical indicators signal a bearish trend with moving averages showing significant sell pressure. The stock exhibits a consistent dividend distribution pattern, with multiple payments scheduled through mid-2026. Recent news coverage highlights the ETF's high-yield strategy but raises concerns about structural risks and capital erosion potential.
The outlook remains cautious due to the bearish technical structure and fundamental concerns about the covered-call strategy's sustainability. Investment opportunity exists for income-focused investors attracted to the dividend yield, but risks include capped upside participation and potential NAV deterioration during market rallies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →
